Background: Classical tumor treatments can fail: surgeries, radiation and chemotherapy not always elongate the life span. Less destructive treatments are possible nowadays. To find and analyse the efficiency of alternate treatments, long term case reports are essential. Aim: To d...
Open access
Research Article10.9734/jocamr/2021/v13i130217
Background: Treatment failure in patients who have chronic myeloid leukemia (CML) using tyrosine kinase inhibitors is common due to development of secondary mutations. Amanita phalloides (Amanita) contains low dose of alpha-amanitin (amanitin),which inhibitis RNA polymerase II (R...
Open access
Research Article10.9734/IJMPCR/2017/38205
Background: Amanita phalloides (Amanita) contains amanitin, inhibiting RNA polymerase II. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. Patients treated with Amanita often gain a stable disease state without further tumor growth. Aim: Se...
Open access
Research Article10.9734/BJMMR/2017/32673
Aims: Amanita phalloides contains alpha-amanitin, inhibiting RNApolymeraseII. Due to overexpression of switch genes in tumor cells, RNApolymeraseII is used to full extent there. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. A patient wit...
Open access
Research Article10.9734/BJMMR/2016/27895
Objectives: Amanita phalloides contains amanitin, inhibiting RNA polymerase II. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. A patient with diagnosed B-cell chronic lymphatic leukemia was treated successfully for eight years with Amanit...
Open access
Research Article10.9734/BJMMR/2016/21897
Background: To date, Chronic Lymphocytic Leukemia (CLL) has been viewed as a malignant disease with tumor growth of cells. This hypothesis should be reviewed. Methods: A patient diagnosed with CLL is treated with Amanita phalloides, containing amanitin, inhibiting specifically tu...
Open access
Research Article10.9734/BJMMR/2015/16449